---
title: "Camp4 Therapeutics Corporation (CAMP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CAMP.US.md"
symbol: "CAMP.US"
name: "Camp4 Therapeutics Corporation"
industry: "Biotechnology"
datetime: "2026-06-19T11:10:11.852Z"
locales:
  - [en](https://longbridge.com/en/quote/CAMP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CAMP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CAMP.US.md)
---

# Camp4 Therapeutics Corporation (CAMP.US)

## Company Overview

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.camp4tx.com](https://www.camp4tx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-19T04:30:13.000Z

**Overall: D (0.65)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 256 / 389 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 160.53% |  |
| Net Profit YoY | -66.69% |  |
| P/B Ratio | 6.94 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 214426795.73 |  |
| Revenue | 3934000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -209.28% | E |
| Profit Margin | -2193.72% | E |
| Gross Margin | -685.16% | E |
| Revenue YoY | 160.53% | A |
| Net Profit YoY | -66.69% | E |
| Total Assets YoY | 68.00% | A |
| Net Assets YoY | -40.08% | E |
| Cash Flow Margin | 30.41% | D |
| OCF YoY | 160.53% | A |
| Turnover | 0.05 | E |
| Gearing Ratio | 70.70% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Camp4 Therapeutics Corporation",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "160.53%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-66.69%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "6.94",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "214426795.73",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "3934000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-209.28%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-2193.72%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-685.16%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "160.53%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-66.69%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "68.00%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "-40.08%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "30.41%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "160.53%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.05",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "70.70%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.48 | 273/389 | - | - | - |
| PB | 6.94 | 363/389 | 5.30 | 3.90 | 0.79 |
| PS (TTM) | 54.51 | 235/389 | 66.74 | 54.24 | 20.29 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |
| 05 | OpGen (OPGN.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-16T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Overweight | 2 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.13 |
| Highest Target | 12.00 |
| Lowest Target | 6.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CAMP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CAMP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CAMP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CAMP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**